Journal article

Docosahexaenoic acid supplementation of preterm infants and parent-reported symptoms of allergic disease at 7 years corrected age: follow-up of a randomized controlled trial

Anoja W Gunaratne, Maria Makrides, Carmel T Collins, Robert A Gibson, Andrew J McPhee, Thomas R Sullivan, Jacqueline F Gould, Tim J Green, Lex W Doyle, Peter G Davis, Noel P French, Paul B Colditz, Karen Simmer, Scott A Morris, Karen P Best



BACKGROUND: Docosahexaenoic acid (DHA, 22:6n-3) supplementation in the prenatal period is associated with a reduction in the incidence of some symptoms of allergic disease. Infants born preterm are at increased risk of allergic disease, but it is unknown if DHA supplementation reduces the risk of childhood allergies. OBJECTIVES: The aim of this study was to determine if supplementation of infants born at <33 wk gestation with high-DHA compared with standard-DHA enteral feeds decreases the incidence and severity of parent-reported allergic disease symptoms at a corrected age (CA) of 7 y. METHODS: This study was a follow-up of an Australian multicenter randomized controlled trial. Infants were..

View full abstract


Awarded by 5-y project grant from the National Health and Medical Research Council (NHMRC), Australia

Awarded by NHMRC

Funding Acknowledgements

This work was supported by a 5-y project grant from the National Health and Medical Research Council (NHMRC), Australia (ID 508003) and Mead Johnson Nutrition. NHMRC Fellowships support MM (Principal Research Fellow APP1061704); RAG (Senior Principal Research Fellow APP1046207), PGD (Practitioner Fellow APP1059111), PBC (Practitioner FellowAPP511117). CTCwas supported through a MSMcLeod Postdoctoral Research Fellowship (MS McLeod Research Fund, Women's and Children's Hospital Research Foundation). The views expressed in this article are soley the responsibility of the authors and do not reflect the views of the NHMRC, Australia.